Physician profile
Jennifer P Miller
NPI 1629323779
$3,772.29
in general payments reported to CMS, 2019-2025
29 companies · $843 in 2025
The $843 reported for 2025 was more than what 97% of Women'S Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $650 · 2023: $1,245 · 2024: $546 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.65 |
| Education | $163.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $797.28 | 2022-2025 | Veozah |
| Abbvie INC. | $482.34 | 2021-2025 | |
| Evofem Biosciences, INC. | $442.35 | 2021-2024 | Phexxi |
| Novo Nordisk INC | $365.12 | 2023-2025 | Wegovy |
| Amgen INC. | $322.72 | 2021-2023 | Evenity, Prolia |
| Pfizer INC. | $192.23 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $173.10 | 2022-2024 | |
| Sage Therapeutics, LLC | $157.10 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $100.37 | 2023-2025 | Slynd |
| Hologic Sales and Service, LLC | $93.84 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Omni Hysteroscope |
| Daiichi Sankyo INC. | $73.80 | 2022 | |
| Lilly USA, LLC | $68.23 | 2023-2025 | Zepbound |
| Exact Sciences Corporation | $62.97 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $62.56 | 2021-2024 | Trintellix |
| Organon LLC | $45.24 | 2022-2024 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $43.46 | 2022 | |
| Supernus Pharmaceuticals, INC. | $40.96 | 2025 | Qelbree |
| Avion Pharmaceuticals | $32.50 | 2023 | Balcoltra |
| Smith+Nephew, INC. | $31.56 | 2024 | Pico 14, Renasys Touch, Pico 7 |
| Myovant Sciences INC. | $26.33 | 2022 | |
| Abiomed | $21.84 | 2024 | Impella |
| Corium, LLC | $19.45 | 2021 | |
| Therapeuticsmd, INC. | $18.98 | 2022 | |
| Sumitomo Pharma America, INC. | $18.06 | 2023 | Myfembree |
| Alkermes, INC. | $16.36 | 2025 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $16.26 | 2024 | Gardasil, Gardasil 9 |
| Axsome Therapeutics, INC. | $15.86 | 2025 | Auvelity |
| Gilead Sciences, INC. | $15.78 | 2023 | Epclusa |
| Dexcom, INC. | $15.64 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.